The demand for an adequate substitute for autograft and allograft is rapidly growing, not the least because of the ageing population. The potential market size for orthobiologics today is already approximately USD 5 billion of which bone graft substitutes account for nearly USD 3 billion.
The amount of bone defects and bone healing problems are expected to increase as population age and life expectancy increases. In addition to this, there is growing demand for less invasive solutions, which minimize adverse events and provide faster recovery.
New bone-graft innovations are replacing traditional own-bone and donor-bone solutions. The increased preference of biocompatible bone-grafts further promotes market growth.